HOME >> MEDICINE >> NEWS
Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy

The muscle destruction associated with Duchenne muscular dystrophy (DMD), the most common childhood form of muscular dystrophy, is halted in mice when supplemental amounts of a naturally occurring enzyme are added to the skeletal muscle.

These results from researchers at the University of California, San Diego (UCSD) School of Medicine are published in the April 16, 2002 issue of the journal Proceedings of the National Academy of Sciences.

Muscle wasting associated with DMD was inhibited after the UCSD team added an enzyme called CT GalNAc transferase to skeletal muscles in mice bred to develop DMD. Normally, CT GalNAc transferase is expressed in another area of the muscle, the neuromuscular junction, where nerves send impulses to muscle fiber. The UCSD team was able to re-position the enzyme so that it was available in the DMD-vulnerable skeletal muscle, which is the structural tissue that supports body movement.

We hope this enzyme can eventually be used as a therapy for Duchenne muscular dystrophy, said Paul Martin, Ph.D., UCSD assistant professor of neurosciences, a member of the UCSD Glycobiology Training and Research Center, and the studys senior author. It has the potential for managing the disease, much like we manage diabetes with insulin medication or injections.

The disease strikes one in 5,000 children, almost exclusively boys, before they reach the age of 6. DMD frequently leaves its victims wheelchair-bound by age 12 and most DMD children die in their early 20s. The disease is caused by a mutation in a protein called dystrophin, which helps anchor muscle fibers to the connective tissue surrounding them.

Losing dystrophin is like losing the foundation of your house, Martin said. Without that foundation, the house falls apart. Without dystrophin, muscles affected by DMD become damaged and break.

Martin discovered the enzyme as he looked for other proteins that might compensate for the disabled dystr
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
15-Apr-2002


Page: 1 2

Related medicine news :

1. Enzyme linked to mania and schizophrenia impairs higher brain functions
2. Enzyme prevents lung damage in premature infants
3. Enzyme found in blood vessels likely target to treat lung injury
4. Enzyme structure holds key to cocaine, heroin metabolism
5. Enzyme replacement therapy found to effectively treat patients with Fabry disease
6. Enzyme level linked to death after angioplasty
7. Enzyme could provide continual fat burning
8. NIH halts use of COX-2 inhibitor in large cancer prevention trial
9. Success of new treatment halts international blood pressure drug trial
10. Researchers identify brain protein that halts progression of Alzheimers
11. New oral medication halts blindness in AIDS patients

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied ... Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress yesterday ... (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web Marketing ... All-Stars Summit. Google Partners is the platform for search marketing agencies to communicate ... and tools necessary to run successful search marketing campaigns. Google Partners also affords ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited by ... recommendations.” No recommendations means CARF found no areas in the OHR program that needed ... 3% of all facilities receive. In addition, Ocean Hills was granted the maximum certification ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, ... ... of Medicine at Mount Sinai Earns National Cancer Institute Designation , The Tisch ... been named a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
(Date:7/30/2015)... 30, 2015  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... year 2015 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... Chief Executive Officer, and Rick Eiswirth , Chief ...
(Date:7/30/2015)... , Net Sales of $1.17 billion represent a decrease of ... of 5.7% constant currency , Reported net loss per ... per share were $1.59, an increase of 0.6% over the ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...  The Company reported second quarter net sales of $1.17 billion, ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 24Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 25Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 26Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 27Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 28Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
Cached News: